Study of Safety and Efficacy of TC011 in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma Patients

This is a multi-center, phase I/II study to determine the safety and efficacy of TC011(CD19 Targeted CAR-T) in adult patients with relapsed or refractory large B-cell non -hodgkin lymphoma.

Trial Details

NCT ID
NCT07473167
Phase
PHASE1 / PHASE2
Sponsor
TICAROS Co., Ltd.
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • TC011
Locations (sample)
  • Seoul, Seoul, South Korea|37.566,126.9784

Key Eligibility Criteria

  • Subjects must meet all criteria including:
  • ≥19 years old, ECOG 0-2, life expectancy ≥12 weeks
  • Histologically confirmed B-cell lymphoma (WHO 2017)
  • Relapsed/refractory after ≥2 prior lines of systemic chemotherapy

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →